Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy(vol14, 1189058, 2023)

被引：0

作者：

Yi, Jia-Qin ^{[1
]}

Huang, Sheng ^{[1
]}

Wu, Miao-Juan ^{[1
]}

Ma, Jie-Hui ^{[1
]}

Huang, Li-Juan ^{[1
]}

Liang, Song ^{[2
]}

Sun, Dan ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Peoples R China

[2] Hubei Third Peoples Hosp, Dept Pediat Rehabil, Wuhan, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2023年 / 14卷

关键词：

perampanel; oxcarbazepine; newly diagnosed focal epilepsy; monotherapy; anti-seizure medications;

D O I：

10.3389/fphar.2023.1295784

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页数：2

共 35 条

[21] Topiramate, carbamazepiine, and valproate monotherapy: Double-blind comparison in children with newly diagnosed epilepsy
Wheless, JW
Neto, W
Wang, S
JOURNAL OF CHILD NEUROLOGY, 2004, 19 (02) : 135 - 141
[22] Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: the open-label Study 342 (FREEDOM Study) (vol 5, pg 274, 2020)
Yamamoto
EPILEPSIA OPEN, 2020, 5 (03) : 518 - 518
[23] Open-label, in-practice study of topiramate monotherapy in children and adolescents with newly or recently diagnosed epilepsy
Guerrini, R
Dlugos, D
Van Oene, J
Lahaye, M
Schwalen, S
NEUROLOGY, 2005, 64 (06) : A189 - A189
[24] Comparison of levetiracetam and carbamazepine as initial monotherapy for newly diagnosed epilepsy in children <16 years old:: A retrospective review
Perry, Michael S.
Holt, P. J.
Olson, L.
Benatar, M.
EPILEPSIA, 2007, 48 : 351 - 351
[25] Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study
Trinka, Eugen
Rocamora, Rodrigo
Chaves, Joao
Moreira, Joana
Ikedo, Fabio
Soares-da-Silva, Patricio
EPILEPSIA, 2020, 61 (10) : 2129 - 2141
[26] Long-term efficacy and safety of perampanel monotherapy in patients with newly diagnosed/currently untreated recurrent focal-onset seizures: FREEDOM Study 342 Extension Phase
Yamamoto, T.
Lim, S. C.
Ninomiya, H.
Kubota, Y.
Shin, W. C.
Kim, D. W.
Shin, D. J.
Hoshida, T.
Iida, K.
Ochiai, T.
Matsunaga, R.
Hiramatsu, H.
Kim, J. H.
EPILEPSIA, 2022, 63 : 25 - 25
[27] Efficacy and Safety of Perampanel Monotherapy in Patients Aged ≥12 to <18 Years with Newly Diagnosed/currently Untreated Recurrent Focal-onset Seizures (FOS): FREEDOM Study 342
Ngo, Leock Y.
Kim, Ji Hyun
Lim, Sung Chul
Yamamoto, Takamichi
Patten, Anna
Malhotra, Manoj
PEDIATRICS, 2022, 149 (01)
[28] Real-world effectiveness and safety of perampanel for children and adolescents with epilepsy: A meta-analysis with at least 1-year follow-up
Weng, Yijun
Ma, Bihong
Lin, Xi
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2024, 122 : 96 - 104
[29] Better seizure control and tolerability over the long term with oxcarbazepine (Trileptal (R)) monotherapy compared with phenytoin in newly diagnosed children and adolescents with partial and generalised tonic-clonic seizures
Guerreiro, M
EPILEPSIA, 2003, 44 : 148 - 149
[30] Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy (vol 60, pg 2437, 2019)
Ben-Menachem, E.
Grebe, H. P.
Terada, K.
Jensen, L.
Li, T.
De Backer, M.
EPILEPSIA, 2021, 62 (04) : 1039 - 1039

← 1 2 3 4 →